Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Laura Mauri, M.D.

Co-Author

This page shows the publications co-authored by Laura Mauri and Robert Yeh.
Connection Strength

13.343
  1. Yeh RW, Kereiakes DJ, Secemsky EA, Steg PG, Mauri L. The DAPT Score in Sweden: Successful Validation, Flawed Interpretation. J Am Coll Cardiol. 2019 01 08; 73(1):113-114.
    View in: PubMed
    Score: 0.903
  2. Yeh RW, Silber S, Chen L, Chen S, Hiremath S, Neumann FJ, Qiao S, Saito S, Xu B, Yang Y, Mauri L. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program. JACC Cardiovasc Interv. 2017 02 13; 10(3):247-254.
    View in: PubMed
    Score: 0.788
  3. Yeh RW, Kereiakes DJ, Mauri L. Reply: Analysis of Dual Antiplatelet Therapy. J Am Coll Cardiol. 2015 Nov 03; 66(18):2056.
    View in: PubMed
    Score: 0.724
  4. Yeh RW, Elmariah S, Doros G, Kereiakes DJ, Mauri L. Mortality risk with dual antiplatelet therapy? Lancet. 2015 Oct 17; 386(10003):1533-4.
    View in: PubMed
    Score: 0.722
  5. Yeh RW, Kereiakes DJ, Mauri L. Reply: Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities. J Am Coll Cardiol. 2015 Sep 08; 66(10):1204-5.
    View in: PubMed
    Score: 0.717
  6. Yeh RW, Elmariah S, Doros G, Kereiakes DJ, Mauri L. Dual antiplatelet therapy duration and mortality - Authors' reply. Lancet. 2015 May 30; 385(9983):2149-50.
    View in: PubMed
    Score: 0.703
  7. Yeh RW, Cohen DJ, Mauri L. Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy. Eur Heart J. 2015 May 21; 36(20):1216-8.
    View in: PubMed
    Score: 0.694
  8. Yeh RW, Czarny MJ, Normand SL, Kereiakes DJ, Holmes DR, Brindis RG, Weaver WD, Rumsfeld JS, Roe MT, Kim S, Driscoll-Shempp P, Mauri L. Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2015 Jan; 8(1):96-102.
    View in: PubMed
    Score: 0.677
  9. Yeh RW, Vasaiwala S, Forman DE, Silbaugh TS, Zelevinski K, Lovett A, Normand SL, Mauri L. Instrumental variable analysis to compare effectiveness of stents in the extremely elderly. Circ Cardiovasc Qual Outcomes. 2014 Jan; 7(1):118-24.
    View in: PubMed
    Score: 0.632
  10. Yeh RW, Mauri L. Choosing methods to minimize confounding in observational studies: do the ends justify the means? Circ Cardiovasc Qual Outcomes. 2011 Nov 01; 4(6):581-3.
    View in: PubMed
    Score: 0.549
  11. Strom JB, Tamez H, Zhao Y, Valsdottir LR, Curtis J, Brennan JM, Shen C, Popma JJ, Mauri L, Yeh RW. Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study. Am Heart J. 2019 06; 212:64-71.
    View in: PubMed
    Score: 0.228
  12. Mauri L, Kirtane AJ, Windecker S, Yeh RW, Dauerman HL, Price MJ, Christen T, Allocco DJ, Meredith IT, Kereiakes DJ. Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. Am Heart J. 2018 11; 205:110-117.
    View in: PubMed
    Score: 0.220
  13. Elmariah S, Doros G, Benavente OR, Bhatt DL, Connolly SJ, Yusuf S, Steinhubl SR, Liu Y, Hsieh WH, Yeh RW, Mauri L. Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis. Circ Cardiovasc Interv. 2018 01; 11(1):e005795.
    View in: PubMed
    Score: 0.210
  14. Yeh RW, Kereiakes DJ, Steg PG, Cutlip DE, Croce KJ, Massaro JM, Mauri L. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2017 Oct 31; 70(18):2213-2223.
    View in: PubMed
    Score: 0.208
  15. Secemsky EA, Kirtane A, Bangalore S, Jovin IS, Patel D, Ferro EG, Wimmer NJ, Roe M, Dai D, Mauri L, Yeh RW. Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States. Circ Cardiovasc Qual Outcomes. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.206
  16. Secemsky EA, Kirtane A, Bangalore S, Jovin IS, Shah RM, Ferro EG, Wimmer NJ, Roe M, Dai D, Mauri L, Yeh RW. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. JACC Cardiovasc Interv. 2016 12 12; 9(23):2376-2386.
    View in: PubMed
    Score: 0.194
  17. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016 Apr 26; 315(16):1735-49.
    View in: PubMed
    Score: 0.187
  18. Wimmer NJ, Secemsky EA, Mauri L, Roe MT, Saha-Chaudhuri P, Dai D, McCabe JM, Resnic FS, Gurm HS, Yeh RW. Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention: An Instrumental Variable Analysis. Circ Cardiovasc Interv. 2016 Apr; 9(4):e003464.
    View in: PubMed
    Score: 0.186
  19. Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, Wiviott SD, Cohen DJ, Massaro JM, D'Agostino RB, Braunwald E, Kereiakes DJ. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J. 2016 Jan 21; 37(4):378-85.
    View in: PubMed
    Score: 0.182
  20. Wasfy JH, Singal G, O'Brien C, Blumenthal DM, Kennedy KF, Strom JB, Spertus JA, Mauri L, Normand SL, Yeh RW. Enhancing the Prediction of 30-Day Readmission After Percutaneous Coronary Intervention Using Data Extracted by Querying of the Electronic Health Record. Circ Cardiovasc Qual Outcomes. 2015 Sep; 8(5):477-85.
    View in: PubMed
    Score: 0.178
  21. Matteau A, Yeh RW, Camenzind E, Steg PG, Wijns W, Mills J, Gershlick A, de Belder M, Ducrocq G, Mauri L. Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015 Sep 01; 116(5):686-93.
    View in: PubMed
    Score: 0.176
  22. Wang ZJ, Zhou YJ, Galper BZ, Gao F, Yeh RW, Mauri L. Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis. Heart. 2015 Oct; 101(20):1631-8.
    View in: PubMed
    Score: 0.176
  23. Mauri L, Yeh RW, Kereiakes DJ. Duration of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2015 04 02; 372(14):1373-4.
    View in: PubMed
    Score: 0.174
  24. Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015 May 26; 65(20):2211-21.
    View in: PubMed
    Score: 0.173
  25. Yeh RW, Mauri L, Kereiakes DJ. Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected]. J Am Coll Cardiol. 2015 Mar 03; 65(8):787-790.
    View in: PubMed
    Score: 0.173
  26. Yeh RW, Mauri L, Wolf RE, Romm IK, Lovett A, Shahian D, Normand SL. Population trends in rates of coronary revascularization. JAMA Intern Med. 2015 Mar; 175(3):454-6.
    View in: PubMed
    Score: 0.173
  27. Elmariah S, Mauri L, Doros G, Galper BZ, O'Neill KE, Steg PG, Kereiakes DJ, Yeh RW. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet. 2015 Feb 28; 385(9970):792-8.
    View in: PubMed
    Score: 0.169
  28. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 04; 371(23):2155-66.
    View in: PubMed
    Score: 0.169
  29. Garg P, Galper BZ, Cohen DJ, Yeh RW, Mauri L. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. Am Heart J. 2015 Feb; 169(2):222-233.e5.
    View in: PubMed
    Score: 0.169
  30. Wasfy JH, Strom JB, Waldo SW, O'Brien C, Wimmer NJ, Zai AH, Luttrell J, Spertus JA, Kennedy KF, Normand SL, Mauri L, Yeh RW. Clinical preventability of 30-day readmission after percutaneous coronary intervention. J Am Heart Assoc. 2014 Sep 26; 3(5):e001290.
    View in: PubMed
    Score: 0.168
  31. Czarny MJ, Nathan AS, Yeh RW, Mauri L. Adherence to dual antiplatelet therapy after coronary stenting: a systematic review. Clin Cardiol. 2014 Aug; 37(8):505-13.
    View in: PubMed
    Score: 0.163
  32. Wimmer NJ, Cohen DJ, Wasfy JH, Rathore SS, Mauri L, Yeh RW. Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable? Am Heart J. 2014 Jul; 168(1):103-9.
    View in: PubMed
    Score: 0.162
  33. Vardi M, Novack V, Pencina MJ, Doros G, Burke DA, Elmariah S, Cutlip DE, Mauri L, Yeh RW. Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis and critical examination of current methodologies. Catheter Cardiovasc Interv. 2014 May 01; 83(6):975-83.
    View in: PubMed
    Score: 0.160
  34. Wasfy JH, Strom JB, O'Brien C, Zai AH, Luttrell J, Kennedy KF, Spertus JA, Zelevinsky K, Normand SL, Mauri L, Yeh RW. Causes of short-term readmission after percutaneous coronary intervention. Circ Cardiovasc Interv. 2014 Feb; 7(1):97-103.
    View in: PubMed
    Score: 0.160
  35. Matteau A, Yeh RW, Kereiakes D, Orav EJ, Massaro J, Steg PG, Normand SL, Cutlip DE, Mauri L. Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study). Am J Cardiol. 2014 Apr 01; 113(7):1146-52.
    View in: PubMed
    Score: 0.158
  36. Wimmer NJ, Resnic FS, Mauri L, Matheny ME, Yeh RW. Comparison of transradial versus transfemoral percutaneous coronary intervention in routine practice: evidence for the importance of "falsification hypotheses" in observational studies of comparative effectiveness. J Am Coll Cardiol. 2013 Dec 03; 62(22):2147-8.
    View in: PubMed
    Score: 0.155
  37. Wasfy JH, Rosenfield K, Zelevinsky K, Sakhuja R, Lovett A, Spertus JA, Wimmer NJ, Mauri L, Normand SL, Yeh RW. A prediction model to identify patients at high risk for 30-day readmission after percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):429-35.
    View in: PubMed
    Score: 0.154
  38. Wimmer NJ, Resnic FS, Mauri L, Matheny ME, Piemonte TC, Pomerantsev E, Ho KK, Robbins SL, Waldman HM, Yeh RW. Risk-treatment paradox in the selection of transradial access for percutaneous coronary intervention. J Am Heart Assoc. 2013 May 24; 2(3):e000174.
    View in: PubMed
    Score: 0.153
  39. Wimmer NJ, Yeh RW, Cutlip DE, Mauri L. Risk prediction for adverse events after carotid artery stenting in higher surgical risk patients. Stroke. 2012 Dec; 43(12):3218-24.
    View in: PubMed
    Score: 0.147
  40. Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand SL, Rumsfeld JS, Messenger JC, Yeh RW. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med. 2012 Aug 13; 172(15):1145-52.
    View in: PubMed
    Score: 0.145
  41. Yeh RW, Rosenfield K, Zelevinsky K, Mauri L, Sakhuja R, Shivapour DM, Lovett A, Weiner BH, Jacobs AK, Normand SL. Sources of hospital variation in short-term readmission rates after percutaneous coronary intervention. Circ Cardiovasc Interv. 2012 Apr; 5(2):227-36.
    View in: PubMed
    Score: 0.141
  42. Yeh RW, Normand SL, Wolf RE, Jones PG, Ho KK, Cohen DJ, Cutlip DE, Mauri L, Kugelmass AD, Amin AP, Spertus JA. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention. Circulation. 2011 Oct 04; 124(14):1557-64.
    View in: PubMed
    Score: 0.136
  43. Stefanescu Schmidt AC, Steg PG, Yeh RW, Kereiakes DJ, Tanguay JF, Hsieh WH, Massaro JM, Mauri L, Cutlip DE. Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). Am J Cardiol. 2019 12 15; 124(12):1813-1820.
    View in: PubMed
    Score: 0.059
  44. Berry NC, Kereiakes DJ, Yeh RW, Steg PG, Cutlip DE, Jacobs AK, Abbott JD, Hsieh WH, Massaro JM, Mauri L. Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. Circ Cardiovasc Interv. 2018 08; 11(8):e005308.
    View in: PubMed
    Score: 0.055
  45. Secemsky EA, Yeh RW, Mauri L. Reply: Duration of the Double Antiplatelet Therapy in Patients With Coronary and Peripheral Arterial Disease: The Key Might Be in the Type of Drug. JACC Cardiovasc Interv. 2017 07 24; 10(14):1468-1469.
    View in: PubMed
    Score: 0.051
  46. Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Steg PG, Massaro JM, Apruzzese PK, Mauri L. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. JACC Cardiovasc Interv. 2017 05 08; 10(9):942-954.
    View in: PubMed
    Score: 0.050
  47. Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D'Agostino RB, Massaro JM, Mauri L. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol. 2017 05 01; 2(5):478-487.
    View in: PubMed
    Score: 0.050
  48. Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, Yeh RW, D'Agostino RB, Massaro JM, Hsieh WH, Mauri L. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation. 2017 May 02; 135(18):1720-1732.
    View in: PubMed
    Score: 0.050
  49. Federspiel JJ, Anstrom KJ, Xian Y, McCoy LA, Effron MB, Faries DE, Zettler M, Mauri L, Yeh RW, Peterson ED, Wang TY. Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. JAMA Cardiol. 2016 Sep 01; 1(6):655-65.
    View in: PubMed
    Score: 0.048
  50. Resor CD, Nathan A, Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Gabriel Steg P, Hsieh WH, Mauri L. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. Circulation. 2016 Oct 04; 134(14):989-998.
    View in: PubMed
    Score: 0.048
  51. Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, Mauri L. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol. 2016 May 31; 67(21):2492-502.
    View in: PubMed
    Score: 0.047
  52. Meredith IT, Tanguay JF, Kereiakes DJ, Cutlip DE, Yeh RW, Garratt KN, Lee DP, Steg PG, Weaver WD, Holmes DR, Brindis RG, Trebacz J, Massaro JM, Hsieh WH, Mauri L. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation. 2016 May 03; 133(18):1772-82.
    View in: PubMed
    Score: 0.046
  53. Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG, Yeh RW, Cohen DJ, Cutlip DE, Massaro JM, Hsieh WH, Mauri L. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. JACC Cardiovasc Interv. 2016 Jan 25; 9(2):138-47.
    View in: PubMed
    Score: 0.046
  54. Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. JACC Cardiovasc Interv. 2015 Oct; 8(12):1552-62.
    View in: PubMed
    Score: 0.045
  55. Secemsky EA, Matteau A, Yeh RW, Steg PG, Camenzind E, Wijns W, McFadden E, Mauri L. Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials). Am J Cardiol. 2015 Jun 15; 115(12):1678-84.
    View in: PubMed
    Score: 0.043
  56. Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA. 2015 Mar 17; 313(11):1113-21.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.